We believe that Boston Scientific stock (NYSE: BSX) is a better pick over Altria stock (NYSE: MO), given its better prospects.

Boston Scientific's (BSX) latest device features a polymer coating, visualization markers and a broader size matrix to treat a wider range of patients.

Boston Scientific's (BSX) FARAPULSE PFA System's performance in the trial is an encouraging sign of the potential utilization of the device in the United States.

Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two stocks presen...

Boston Scientific surprised the Street with better-than-expected ADVENT study results; Farapulse delivered better procedural success rates with good safety and lower procedure times. Farapulse will...

Boston Scientific (BSX) was the best-performing stock in the S&P 500 after the medical device maker reported positive results from a clinical trial for its system to treat patients with atrial fibr...

Boston Scientific (NYSE:BSX) shares rose almost 5% after the biotechnology company reported positive results from its pivotal atrial fibrillation (AF) trial. The trial compared the company's FARAPU...

Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.

Boston Scientific's (BSX) POLARx enables doctors to expand and modify the new POLARx catheter to match a patient's unique anatomy during an ablation treatment.